A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

Peritoneal Cancer ◽

Saracatinib (AZD0530) plus weekly paclitaxel in platinum resistant ovarian, fallopian tube or primary peritoneal cancer

http://isrctn.org/> ◽

10.1186/isrctn32163062 ◽

2012 ◽

Author(s):

Lee Webber

Keyword(s):

Fallopian Tube ◽

Weekly Paclitaxel ◽

Peritoneal Cancer ◽

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.10.001 ◽

2018 ◽

Vol 151 (3) ◽

pp. 422-427 ◽

Cited By ~ 7

Author(s):

Bradley J. Monk ◽

James T. Kauderer ◽

Katherine M. Moxley ◽

Albert J. Bonebrake ◽

Summer B. Dewdney ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

10.1200/jco.2015.33.15_suppl.5578 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5578-5578

Author(s):

Isabelle Ray-Coquard ◽

Ioana Braicu ◽

Regina Berger ◽

Sven Mahner ◽

Jalid Sehouli ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Hsp90 Inhibitor ◽

Weekly Paclitaxel ◽

High Grade ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

10.1200/jco.2018.36.15_suppl.5567 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5567-5567 ◽

Cited By ~ 2

Author(s):

Nicole Concin ◽

Ioana Braicu ◽

Pierre Combe ◽

Isabelle Laure Ray-Coquard ◽

Florence Joly ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase Ii ◽

Hsp90 Inhibitor ◽

Weekly Paclitaxel ◽

High Grade ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

10.1200/jco.2015.33.15_suppl.5516 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5516-5516 ◽

Cited By ~ 1

Author(s):

Rachel N. Grisham ◽

Michael S. Gordon ◽

Wael A. Harb ◽

Carol Aghajanian ◽

D. Scott McMeekin ◽

...

Keyword(s):

Fallopian Tube ◽

Dose Escalation ◽

Weekly Paclitaxel ◽

Dose Escalation Study ◽

Phase Ib ◽

Peritoneal Cancer ◽

Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

10.1200/jco.2016.34.15_suppl.e17038 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e17038-e17038 ◽

Cited By ~ 1

Author(s):

Nicole Concin ◽

Ioana Braicu ◽

Regina Berger ◽

Sven Mahner ◽

Jalid Sehouli ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Hsp90 Inhibitor ◽

Weekly Paclitaxel ◽

High Grade ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Case Medical Research ◽

10.31525/ct1-nct03907527 ◽

2019 ◽

Author(s):

Keyword(s):

T Cells ◽

Fallopian Tube ◽

Immune Cells ◽

Peritoneal Cancer ◽

Car T Cells ◽

Platinum Resistant ◽

Car T

Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2011.07.017 ◽

2011 ◽

Vol 2011 ◽

pp. 78-79

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Clinical Activity ◽

Fallopian Tube Cancer ◽

Peritoneal Cancer ◽

A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Annals of Oncology ◽

10.1093/annonc/mdx372.061 ◽

2017 ◽

Vol 28 ◽

pp. v352-v353

Author(s):

K.N. Moore ◽

K.A. Cadoo ◽

S. Chambers ◽

S. Ghamande ◽

G. Konecny ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Multicentre Phase ◽

Peritoneal Cancer ◽

A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.09.048 ◽

2020 ◽

Vol 159 (3) ◽

pp. 692-698

Author(s):

M.R. Hall ◽

H.-M. Dehbi ◽

S. Banerjee ◽

R. Lord ◽

A. Clamp ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Low Dose ◽

Controlled Trial ◽

Peritoneal Cancer ◽

Metronomic Cyclophosphamide